Novimmune SA raises CHF 60 million

Venture-capital backed Novimmune SA of Switzerland has secured CHF 60 million ($66 million) in new capital, its largest financing round in five years. The monies will be used to advance its pipeline of clinical-stage monoclonal antibodies.